Neurocrine Biosciences Stock Alpha and Beta Analysis
| NBIX Stock | USD 125.65 0.65 0.52% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Neurocrine Biosciences. It also helps investors analyze the systematic and unsystematic risks associated with investing in Neurocrine Biosciences over a specified time horizon. Remember, high Neurocrine Biosciences' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Neurocrine Biosciences' market risk premium analysis include:
Beta 1.35 | Alpha (0.42) | Risk 2.93 | Sharpe Ratio (0.09) | Expected Return (0.26) |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Neurocrine |
Neurocrine Biosciences Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Neurocrine Biosciences market risk premium is the additional return an investor will receive from holding Neurocrine Biosciences long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Neurocrine Biosciences. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Neurocrine Biosciences' performance over market.| α | -0.42 | β | 1.35 |
Neurocrine Biosciences expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Neurocrine Biosciences' Buy-and-hold return. Our buy-and-hold chart shows how Neurocrine Biosciences performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Neurocrine Biosciences Market Price Analysis
Market price analysis indicators help investors to evaluate how Neurocrine Biosciences stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Neurocrine Biosciences shares will generate the highest return on investment. By understating and applying Neurocrine Biosciences stock market price indicators, traders can identify Neurocrine Biosciences position entry and exit signals to maximize returns.
Neurocrine Biosciences Return and Market Media
The median price of Neurocrine Biosciences for the period between Tue, Aug 27, 2024 and Mon, Nov 25, 2024 is 120.17 with a coefficient of variation of 7.45. The daily time series for the period is distributed with a sample standard deviation of 9.05, arithmetic mean of 121.43, and mean deviation of 5.69. The Stock received a lot of media exposure during the period. Price Growth (%) |
| Timeline |
1 | Neurocrine ending development of luvadaxistat amid failed study | 09/12/2024 |
2 | Disposition of 930 shares by Lyons Gary A of Neurocrine Biosciences at 42.76 subject to Rule 16b-3 | 10/10/2024 |
3 | State Street Corps Strategic Acquisition in Neurocrine Biosciences Inc | 10/17/2024 |
4 | Decoding Neurocrine Biosciences Inc A Strategic SWOT Insight | 10/31/2024 |
5 | Disposition of 2000 shares by Sherwin Stephen A of Neurocrine Biosciences subject to Rule 16b-3 | 11/04/2024 |
6 | Neurocrine Biosciences Receives Buy Rating from HC Wainwright | 11/05/2024 |
7 | Neurocrine Biosciences Strong Earnings Are Of Good Quality | 11/08/2024 |
8 | Xenon Q3 Loss Narrower Than Expected, Pipeline Development in Focus | 11/13/2024 |
9 | BB Biotech AG Adjusts Stake in Ionis Pharmaceuticals | 11/15/2024 |
10 | Victory Capital Management Inc. Increases Holdings in Neurocrine Biosciences, Inc. - MarketBeat | 11/19/2024 |
11 | Helpr Employer-Subsidized Family Care App with Patented My Choice Technology Expands Service to 150 Countries, Adds New Features | 11/21/2024 |
About Neurocrine Biosciences Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Neurocrine or other stocks. Alpha measures the amount that position in Neurocrine Biosciences has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2021 | 2022 | 2023 | 2024 (projected) | Days Sales Outstanding | 59.73 | 85.81 | 84.97 | 89.22 | PTB Ratio | 5.86 | 6.7 | 5.77 | 6.13 |
Neurocrine Biosciences Upcoming Company Events
As portrayed in its financial statements, the presentation of Neurocrine Biosciences' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Neurocrine Biosciences' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Neurocrine Biosciences' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Neurocrine Biosciences. Please utilize our Beneish M Score to check the likelihood of Neurocrine Biosciences' management manipulating its earnings.
| 7th of February 2024 Upcoming Quarterly Report | View | |
| 1st of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 7th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Neurocrine Biosciences
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Additional Tools for Neurocrine Stock Analysis
When running Neurocrine Biosciences' price analysis, check to measure Neurocrine Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Neurocrine Biosciences is operating at the current time. Most of Neurocrine Biosciences' value examination focuses on studying past and present price action to predict the probability of Neurocrine Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Neurocrine Biosciences' price. Additionally, you may evaluate how the addition of Neurocrine Biosciences to your portfolios can decrease your overall portfolio volatility.